vaccine-preventable subject free possible current such assert subsequent additional digital re-hosted educational non-commercial computer-extracted Computer-extracted such unusual odd Original 2021-11-05 e-Preven lugs-A Vaccine-Preventable Other Other Other Post-Exposure live bacte- rial viral human bacterial viral global Last indigenous acellular Last Wild-virus infectious own immune Vaccine-Preventable paralytic 1964-1965 Vaccine-Preventable detailed discus- under- basic useful Many excellent available additional infectious basic active human human usu- effective few own complex primary foreign “ non-self specific foreign effective live alive natural such Other such long certain effective anti- good specific temporary immune common passive last 1-2 full-term same certain red small intravenous large whole red major heterologous homologous human homologous human available serum sick- important human human specific human human many different con- many different prima- human hu- high other smaller post-exposure prophy- several antigen-speciﬁc cellular passive temporary active many active natural general infectious many immunologic certain many active administra- identical natural potential similar natural Many vaccina- maternal such nutritional coexist- basic live different “ available live live whole partial vac- bacterial bacterial genetic live similar natural better small large immune live ineffective such natural much milder natural adverse similar natural effective possible live virtu- identical natural wild severe certain live original disease-causing live due transpla- vac- sensitive labile available live live yellow live bacterial live bacterial oral and-or fractional vac- polysac- entire general protective protective second third alive noninfectious immunodeﬁ- pathogenic live antibody-containing natural humoral cellu- periodic supplemental critical whole bacterial reactogenic available inactivated whole whole fractional such acellular diphthe- pneumococ- meningococcal fractional certain available pneumococcal meningococcal independent able independent clear imma- 3-5 humoral acellular functional immunogenic inactivated adverse inactivated “ less functional nant vac- little late immune independent immu- mul- genetic nant certain genetic likely oral possible genetic foreign own many different previous Many important appropriate immuniza- antibody-containing live simultaneous nonsimultaneous differ- subsequent same next adminis- such immune antibody-containing related antibody- different subsequent same same certain such live viral necessary least anti- less Oral yellow few significant yellow necessary other recent inter- various complete red normal contact Whole 7-11 immune single-antigen oral Simultaneous non-simultaneous simultaneous yellow simultaneous decreased adverse simultaneous sepa- least possible local systemic feasible preferable separate eligible important appropriate recent one- unvaccinated vaccine-eligible same same same Non-simultaneous different simulta- same different interval inactivated live simulta- inactivated live with- yellow least least yellow single live due theoretical immunologic oral other other few oral other same multi-dose multi-dose possible up-to-date necessary normal important effective minimum important other other different accept- able other Nonsimultaneous live oral yellow individual single close effective- next minimum acceptable below-even earlier-the second PRP-OMP complete next next neces- sary single multiple periodic single-antigen multiple-dose single second immune second dose protective immune second third few notable periodic additional rare older long similar mild natural local live effective natural common adverse similar mild natural common adverse incu- allergic peak 7-10 similar natural large common adverse local such mani- likely life-threatening life-threatening unrelated public private medical Most temporary general likely life-threatening true anaphylactic serious life-threatening general hypotonic additional hypotonic high severe severe allergic re- medical severe allergic reac- animal common yellow able anaphylactic anaphylactic-like adverse reasonable yellow anaphylactic hypersensitive penicil- absolute informa- encephalopathy temporary severe recent mg-kg daily certain theoretical live theoretical pregnant fetal severe due uncontrolled oral live next safe Low-dose short-term less topical includ- signiﬁcant human special general same recommen- other live serious adverse next summarizes current HIV-infected severe vaccina- live de- common such upper respira- contraindica- unrelated multiple flnvalid low-grade upper multiple prior adverse live oral interval appropriate circu- certain true Such circum- common invalid minor ill- anaphylactic certain mild such low-grade upper Several large young and-or large earlier small such mild necessary immuni- hot antibiotic antiviral live conva- adverse pregnant breast-feeding noncommuni- con- greater other fetal passive able maternal chronological other high-risk positive chronic perinatal trans- non-severe non-specific allergy available Non-anaphylactic such true more Non-anaphylactic adverse unrelated relevant oral personal same most false negative same 4-6 routine 1989-1991 major preschool-aged large preschool-aged large urban primary inad- preschool-aged many low preschool-aged limited clinic loca- important low general simultaneous invalid bureaucratic other hospital outpatient oppor- vaccina- vacci- ﬁnancial other such non-simultaneous invalid bureaucratic other immunlzat public Missed min-a up-pawl oral other minimum important simultaneous invalid simultaneous 2-year-old Special oral several gen- eral previous other live primary supplementary other immune live maternal maternal pregnant gastrointestinal immu- important wild adverse diphtheritic aerobic gram-positive specific bacterio- genetic non-toxigenic severe selective other severe toxigenic responsible local gram-positive fox selective normal diphtheroid 2-5 1-10 mucous exudative 2-3 high responsible major myo- low Clinical severe re- due inadequate Clinical 2-5 l-lO mucous clinical indistinguishable common nasal dis- blood-tinged white nasal mild appar- poor systemic antibiotic tonsillar common substantial systemic insidious low-grade 2-3 bluish-white small soft greyish-green black minimal forcible Extensive severe rapid high severe submandibular anterior lymphadenopathy characteristic in- mem- cutaneous common responsible high natural other recent non-toxigenic general less other toxigenic Other mucous vulvo-vaginal external Most attrib- utable local tis- frequent Most attributable local common higher < usu- soft frequent third diaphragmatic Other due overall higher little last foreign streptococcal membranous infectious other viral post-tonsillectomy foreign mem- clinical imperative presumptive critical tonsillar selective hemolytic helpful clinical multiple club-shaped Other “ direct clinical diagnostic antibiotic positive presumptive and-or low non-protective commercial several slant 18-24 clinical highest highest signiﬁcant Native geographic cur- asymptomatic high asymptomatic several 1940-1993 1980-1994 1-4 5-9 10-19 20-29 30-39 40-49 provisional unknown i dur- present variable less more Effective antibiotic major mortal- top 140-150 rapid widespread high cutaneous non-toxigenic cutaneous lower 0-5 unimmunized immunized current distri- many protective current due high adequate primary apparent toxigenic Russian several other former important young nearest Quarantine 639- antibiot- adequate provisional clinical appropri- other former many up-to-date 48-hour 48-hour less U-day more m Formalin-inactivated contagious tive negative less old old 7- 10-day oral cutaneous nontoxigenic early early usual most optimal last additional protective international clinical table diphtheria-tetanus-acellular fourth available valid second third old older 4-8 12-15 6-12 old elementary necessary fourth primary last dose older due third dose 6-12 second primary fourth available fourth old older table primary least third dose second subse- ultimate next frequent adverse systemic systemic dose 4-8 6-12 last active less Adverse common self-limited pal- pable several other systemic uncommon severe local high severe systemic such severe allergic reac- previous additional mild deliver- able refrig- 2°-8°C 35°-46°F direct cutaneous toxigenic appropriate preliminary clinical epidemiological early presumptive least negative close other oral close immuni- antibiotic immunized less diph- unknown immediate primary ac- current toxoid-con- recent Other adequate antibiotic additional 10-day follow-up Most older convulsive skeletal 5th clinical fatal human same human protective passive active immuni- gram-positive drumstick sensitive resis- usual 10-15 other Manure-treated agricultural normal human gram-positive spore-forming important human peripheral spinal sympathetic nervous nervous 1989-1990x \ 3-21 clinical uncon'mon cephalic rare 3-4 complete major dead other organ- several central nervous peripheral spinal sympathetic nervous typical clinical unopposed nervous further central ner- vous longer higher neonatal clinical different same anatomic many Local ized fatal rare ear present middle cranial trismus swal- abdominal Other 2°-4°C normal episodic rapid last several 3-4 newborn unhealed umbilical unsterile common rare vocal and-or sustained autonomic nervous and-or abnormal hospital-acquired elderly common fatal tetanus obvious direct several gradual newborn umbilical due Other nosocomlal pulmonary higher extreme tetanus contagious 1947-1994 complete medical more clinical bacterial positive severe dental encepha- such due low clinical bacteriologic iso- populated hot organic intestinal appar- major Most severe extensive recent higher likely prop- elective deep dental contagious human human vaccine-preventable infectious contagious early late late notiﬁable 500-600 50-100 constant all-time nationwide largest older non-Hispanic higher primary high last Central American prenatal umbilical unsterilized um- bilical 1989-1990 n=86 non-acute other outdoor 1982-1992 1989-1990 uumsorotcam 20-39 40-59 1989-1990 ol 1989-1990 “ on- lull-bio moon-4 Other insulin-dependent parenteral ﬁve other conceivable intestinal unrecalled safe useful tetanus prior formaldehyde-treated protective available alumi- equal higher single periodic older younger fourth greater minimal protective protective complete clinical last last rare primary most minimal protective last routine small minimal protective other clean last fewer least old less 6-8 second second third fourth primary less third fourth primary old older much local higher common older Routine elementary last last 6-12 primary systemic systemic third dose 6-12 second next next frequent boost- adverse reac- Adverse adverse common self-limited palpable injec- adsorbed several other systemic uncommon local unusual extensive painful swell- severe reac- high severe local systemic such generalized neurologic few pe- ripheral recent available relation- severe allergic previous useful appropri- severe routine minor toxoid-containing other clean pediatric teta- 2°-8°C 35°- compo- practical useful proper important active passive primary toxoid clean minor 0-2 prior uncer- prior temporary protective other last dose last dose noncontagious 40-60 Most older high tious 20th common major widespread aver- unimmunized pertus- major due small aerobic gram-negative fastidious special multiple antigenic active ﬁlamentous he- responsible clinical subsequent clinical summary Gram-negative special antigenic active ﬁlamentous epithelial 1-6 5-10 insidious similar upper nonspecific 1-2 toxin-mediated bacte- para- pulmonary secre- anti- recent alveolar clinical insidious runny low-grade occasional similar common severe 1- second paroxysmal paroxysmal pa- numerous due thick long characteristic high-pitched cyanotic young ill distressed patient usu- normal first same last gradual less paroxysmal subsequent many minimal milder indistinguishable other upper uncommon cough other susceptible unimmunized underimmu- ﬁrst multiple highest pertussis-associated common pertussis-related secondary bacterial 1989-1991 such common encephalopathy younger old Other serious severe subdural due highest younger character- istic physical useful young atypical safe immunogenic unknown 1989-1991 1989-199 direct successful posterior ob- selective prepared antibiotic effective trimethoprim-sulfamethoxazole ﬁrst second nasopharyn- direct direct low variable white present classical lympho- greater mild medical supportive Erythro- communicabil- trimethoprim-sulfamethoxazole other controlled clinical other close four-dose minimal primary current current Clinical least parox- inspiratory post-tussive other apparent clinical labora- laboratory-conﬁrmed compatible clinical appropriate endemic sporadic outbreak de- least direct nasopharyngeal low variable probable conﬁrmed respiratory airborne summer-fall paroxysmal Secondary 5-910-1415-1920-2930-394IH 1940-1993 1980-1993 unclear young silent infrequent little distinct seasonal communicable secondary unimmunized contagious maximum conta- Secular common 1940-1945 annual 1980-1990 ~1 popula- 1992-1993 largest Large Cincin- clear 3-5 likely > re- 1980-1989 formalin-inactivated clinical mid- current available single ﬁve-dose old older 4-8 4-8 12-15 6-12 old elementary necessary fourth primary last dose older due third dose 6-12 second primary whole-cell fourth available fourth recent more last last previous primary complete vacci- nated mid-1930s 5-dose fourth Several acellular different compo- ﬁlamentous hemag- acellular equal fourth primary initial three-dose initial clinical early equivalent whole- Several clinical relative protective primary whole-cell fourth ﬁfth routine available local other common systemic whole-cell primary 4-to 8-week fourth whole-cell 6-12 third adequate fourth whole least third fourth primary single whole- necessary fourth primary in- protective frequent older routine primary simulta- neous whole-cell oral and-or similar vac- simultaneous whole-cell common compo- Sterile re- 6-10/ such more common self-limited symp- tomatic adverse fewer local adverse fourth ﬁfth whole whole moderate-to-severe systemic high inconsolable hypotonic-hyporesponsive short-lived Other more severe such prolonged rare temporal major adverse best available individual local systemic inconsolable hypotonic-hyporesponsive previous local other systemic hypotonic-hyporesponsive severe adverse likely lower immediate anaphylactic diph- and-or speciﬁc true further serious such 1976-1979 large serious neurologic 2-36 neurologic age-matched signiﬁcant conﬁ- interval 1.7-6.5 serious Most serious neurologic sei- least neurologic normal subse- neurologic permanent attributable wide small subject enough valid neurologic subsequent serious neurologic permanent neurologic encephalopathy valid due identifiable prior higher other identiﬁable severe shock-like hypotonic- comprehensive available available pertussis- excess 0-10.5 available chronic severe allergic prior due identifiable such upper due adverse subsequent due identiﬁable shock-like hypotonic-hyporesponsive inconsolable adverse additional precautionary adverse previous valid moderate young possible potential neurologic neurologic more certain neurologic uncontrolled progressive other neurologic stable neurologic idiopathic cerebral developmental small whole-cell full smaller altered likely full smaller standard neurologic neurologic full severe adverse additional typical clinical cuiture- docu- typical clinical culture-proven out- such pertus- other certain 2°-8°C 35°-46°F susceptible normal other Other adverse other oppo- other includ- due modern medical trivial greater distinct admin- many adverse critical many congenital neurologic manifest other systemic inevitable underly- central-nervous such febrile largest likely non-SIDS tempo- recent responsible other more subtle neurological such hyperactiv- infantile progres- sive degenerative scientific other relative vacci- inci- accel- last major annual less 1977-1979 allega- adverse major < 4-5 Most Acellular / high epidemic epidemic risk-beneﬁt hypothetical overall annual residual annual more 10-fold weekly lengthy many unreported useful epidemiologic highest greatest severe recent spinal classic compatible lower recognizable polio- transient gastrointestinal stable acid small ether-insensitive minimal sero- primary gastrointestinal present little several local summary local spread central nervous aseptic sensory aseptic non-CNS Asymptomatic central nervous anterior typical variable clinical presen- inapparent subclini- paralytic able clinical laboratory central nervous complete less poliovirus upper gas- trointestinal abdominal indistinguishable other viral aseptic and-or several similar last complete normal biphasic initial minor 1- major superﬁcial deep severe dimin- ished deep asymmetrical paralytic Pa- permanent common paralytic 1969-1979 most cranial combi- spinal paralytic cerebrospinal diagnostic genomic deter- “ wild-like high 4-fold white mg-100 possible seasonal 7-10 stool 3-6 6-20 3-35 inapparent asymptomatic immune fecal-oral important oral-oral seasonal tropical infectious susceptible poliovi- present due vaccine-associated Secular initial least early maternal high continual para- lytic rare immediate pre-vaccine frequent primary immu- natural paralytic early paralytic last paralytic endemic wild annual vaccine-type oral susceptible 1980-1991 Oral 4-30 4-30 4-30 illness 4-60 oontact-waccine same non-household endemic epidemic less Christian paralytic poliomy- non-paralytic non-Amish para- lytic non-paralytic mean early adminis- 1950-1993 inactivated general less Christian non-paralytic 7-18 non-paralytic [ non-Amish primary paralytic least monovalent oral oral available 1969- constant routine major local lifelong inter- intestinal wild important other enterovi- other paralytic small paralytic healthy 2-month 6-week necessary routine third 15-18 Adminis- third equal due Age-Interval Initial 6-12 6-12 6-8 4-8 Primary 6-8 6-12 necessary necessary third primary fourth lupplementa third primary fourth supplementary such immunodeﬁcient major paralytic signiﬁcant local paralytic wild addi- expensive primary early second little necessary third 6-12 second primary primary approxi- current clinical effective lifelong one-time high necessary such > necessary immune small unknown local wild same possible necessary greater laboratory health-care f possible 1-2 6-12 separate \necessary complete infec- endemic epidemic speciﬁc current wild previous available primary feasible higher recommended 1- 2-month third less available least 1-2 available least available single complete primary further supplementary primary full last necessary sched- small OPV-associated paralytic such prompt complete extreme OPV-associated polio- virus-vaccine usual small fecal-oral acceptable strong ultimate full allergic further strepto- sensitive anaphylactic anaphy- lactic such temporary mild low average Serious severe available paralytic paralytic 1980-91 due familial immune substi- general pregnant immediate due vaccine-type 1980-1991 overall Most healthy Vaccine-associated paralytic likely immunodeﬁ- Other immune available likely such adverse vaccine-associated small susceptible close personal serious adverse available dry lower frozen freeze-thaw total cumulative 2°- 35°-46°F multiple-dose 2°-8°C 2°-8°C 35°-46°F clear color- preliminary clinical epidemiological paralytic appropriate local appropriate viral paralytic immediate vaccine-associated dis- outbreak how- unvaccinated epidemic uncertain last docu- last wild paralytic provisional 30-40 paralytic new new post-polio post-polio ermine-lam Last Last free rare residual female post-polio paralytic tious Several post-polio 534-0475 655-5301 dreaded lifelong human single-stranded structural viral important responsible viral responsible antigenic recent glycopro- important ob- acidic short contagious acute viral universal frequent due low regional 2-3 Secondary 5-7 10-12 2-4 systemic primary regional primary subsequent viral regional distal second initial other nasopharynx 3-4 Clinical 7-18 prodrome 2-4 1-7 charac- high 103°-105°F runny and-or mucous pathognomonic 1-2 1-2 blue-white bright red buccal maculopapular 5-6 upper next gradu- maculopapular discrete upper most involved same Other Other anorexia common viral common rash 1-15 head- stiff ap- residual many rare degen- erative central nervous due persistent Average month- insidious progressive myoclonic 85-1992 u 5-19 5-19 higher spontaneous deﬁnable 1-2 recent other higher young common acute Other natural pleural maculopapular petechial urticarial vesicular live local severe infec- wild young residual mild discrete short high 105°-106°F mucous certain typical several acute high severe diarrhea dehy- bacterial high African present subclinical common 12-14 circumoral rash punc- most skin positive beta- hemolytic 3-4 high red clinical red circumoral maculopapular lace-like other febrile prominent desquama- prominent staphylococcal syn- s other few Laboratory secre- viral viral prior signiﬁcant measles- single neutraliza- enzyme common available non-detectable detectable primary international probable epidemio- probable prob- able possible local indigenous entire f 15-19 < 1-4 religious exempt Susceptible 950-1 1980-1994 human asymptomatic large ofﬁce communicable secondary susceptible 3-4 actual More 5-9 more 2-3 epidemic indigenous lowest annual popu- 1980-1988 school-aged ﬁrst school-aged appropri- unvacci- ated median death-to- dramatic distribu- largest ﬁrst pro- Thirty-ﬁve school-aged old highest 1-4 Overall highest lowest non-Hispanic higher non- ioof-i- ~- '- Preschool-age School-age '- .- 12-15 16-59 _- unvaccinated 1965-1992 1989-1991 medical more Preschool-aged predominant large Most small senior high 1985-1993 987-92 989-90 990-92 1989-90 1988-89 1990-91 986-87 989-90 988-90 1989-90 least hospital direct medical 1989-1991 > provisional measles-associated death-to-case Twenty-eight fatal largest major school-aged great- school-aged vaccinated large school-aged ﬁrst annu- major school-aged annual school-aged preschool-type annual outbreaks preschool-type promi- school-aged large several unvaccinated black 1989-1991 important 1989- low cover- low many large preschool-aged early experi- preschool-type few second black likely white less 1989-1991 high other many young due wild smaller higher wild susceptible younger many other includ- continent-wide major Vaccine-induced high current high clinical single efﬁcacious preschool-aged final lowest annual provisional religious exempt preschool-aged chil- largest preschool-aged lowest annual propor- preschool-aged school-aged viral avail- able live several Two-dose Two-dose 12-15 similar natural single few natural humoral cellular lower natural many few secondary subclinical communicable greater older lower 12-14 maternal 12-15 routine susceptible due maternal routine two-dose recom- second primary several second pos- sible second low anti- few measles-mumps-rubella second administrative consider- susceptible due lower second important first primary 12- junior high 12-15 ogic 16-27 negative adequate physician-diagnosed live unknown unknown American routine two-dose recommenda- second middle junior high additional second least other other educational post-high two-dose other high new other other international endemic other unvac- least ﬁrst live less last unknown unknown necessary Post-exposure permanent temporary expo- ml-kg maximum suscep- tible highest Live passive older replica- subsequent allergic 5-12 common due apparent thrombocytopenic uted natural temporal such extreme egg-allergic potential such upper o antibiotic preschool-aged due 1989-1991 unvaccinated other recent upper multiple previ- ous immune immune immunosuppressive low topical steroid prepara- immunosuppressive immunodeﬁcient antibody-containing immune whole red intravenous such immune prophy- intravenous severe symptomatic serious unusual asymptomatic symptomatic HIV-infected asymptomatic symptomatic infected asymptomatic necessary susceptible infected ﬁltrable same anti- cross-react single-stranded various human cerebrospinal generalized military light regional 12-25 low-grade 14-18 asymptomatic lower preschool-aged clinical postpubertal respiratory regional such infected characteristic aseptic Clinical 14-18 14-25 nonspeciﬁc minimal common infected unilateral bilateral single salivary asymptomatic addi- tional nervous aseptic common inﬂammatory cerebrospinal higher such rare uncommon testicular common postpubertal postpubertal abrupt testicular last pa- rare sensorineural unilateral vestibular sudden ovarian infre- reversible single many temporal few compatible myo- symptomatic rare good endocardial other congenital fetal how- young larger last spontaneous complete common accom- abnormal renal Other such hematological paroxysmal nocturnal other thyroid lacrimal infre- 1-3.4 recent ef- metabolic systemic dis- viral bacterial other epidemic ongoing bilateral involve- clini- cal particular clinical includ- insensitive reliable available routine diagnostic available sensi- available detectable first few several second clinical acute unilateral bilateral salivary other apparent human asymptom- atic nonclassical airborne transmis- direct infected endemic similar infectious active reportable oc- 1983-1985 1.3- relative 3,000- lowest Clinical unilateral bilateral salivary other apparent saliva active 1968-1993 1980-1993 .- 1982-1993 early 5-9 highest late older urban-suburban serologic large young such mobiliza- vac- short-lasting early live durable lifelong immu- subclinical communicable Clinical older susceptible Most immune necessary immune immune safe immune effective harmful Adverse adverse large-scale few lower 2-6/ inadequate aseptic sensorineural live viral extreme cau- appro- vacci- egg-allergic moderate mild upper antibiotic other Low-grade rare f immune immune immunosuppressive low topical steroid prepara- immunosuppressive chemotherapeutic theoretic fetal antibody-containing immune whole red intravenous least antibody-containing Other susceptible important young limited sub- susceptible older oral necessary includ- compre- hensive comprehensive severe susceptible af- fected local Such effective medical religious other least last affected other vaccine-preventable outbreak immu- school-age little variant third little red separate medical viral viral simmer-baby nasal acute 1962-65 widespread Australian early such enveloped single antigenic other group- unstable low lipid 5-7 regional 12-23 second more \ maculopapular respiratory regional 5-7 transplacental mitotic subclinical rare older 1-5 low-grade upper pruritic last several posterior cervical many integral Other soft diagnostic uncommon rare same last chronic rare approximate secondary low thrombocytopenic common cerebral intrarenal last Additional late progressive circumoral high 4-5 abrupt reticular systemic similar last longer Other prominent positive female rare rare rare surgical/spontaneous neonatal fetal dangerous gestational fCongenital aseptic common early important main vaccina- epidemic ﬁnancial emotional disastrous early lead- fetal con- Spontaneous common rare overall third greater uncomplicated congenital common sole manifesta- congenital such ventricu- possible mental other fre- progressive older low high cell-mediated characteristic clinical cal notori- unreliable urine time-consuming many signiﬁcant positive present primary undetectable rapid negative inter- positive important pregnant sensitive simple > 4-fold diagnostic recent clinical serologic Complement detectable 24-fold primary sensitive available easy rapid sensitive similar available false-positive due sensitive low normal positive useful diagnostic 15-minute sensitive airborne infected subclinical approxi- human highest contagious contagious large susceptible Secular notiﬁable largest annual fewer < lowest annual several ap- < 5-19 20-39 last major epidemic 1964-1965 large other military rigorous other recent li-t-ii- p- < 5-19 \1982-1993 1980-1993 1982-199A 1969-1993 union-l susceptible live rubella-containing first largest annual Fewer dramatic due susceptible young moderate high older 1990-1991 higher joint human other rubella-infected aborted 25-30 human safe immunogenic lifelong signiﬁcant demon- high protective communicable cul- subclinical rare measles- susceptible pregnant Particular positive serologic physician- acceptable serological prior serological adverse immune effective harmful dis- common lymphadenopathy common susceptible such objective clinical 1-3 1-3 susceptible such rare female 1-3 susceptible More common natural Other chronic persistent arthri- natural vaccine-associated available joint adverse chronic consistent chronic institu- immune receive moderate mild upper antibi- otic other impaired immune immunosuppressive low topical steroid prepara- immunosuppressive chemotherapeutic theoretic fetal next antibody-containing im- whole red intra- venous least antibody-containing necessary Previous human immune anti-Rho immune 6-8 other neces- human situa- mild serious pregnant pregnant next pregnant wild such likely next theoretical susceptible susceptible vaccine-induced maximum theoretical low routine new old 122.8-14.0 pregnant small theoretical low several high —Intensive susceptible postpubertal susceptible young possible in- susceptible hospi- important susceptible such two-dose adverse attributable vac- childbearing- similar epidemiologi- infectious separate early serologic fecal oral facili- poor personal poor intimate Non-A non-B epidemiologi- due transmit- due fecal-oral distinct hepati- v iral several admin- human early transmis- further complete seroiogic natural effective enteric human yellow Australian chronic hepatocellular human least chronic primary hepatocellular common chronic chronic world- wide second human die chronic small double-shelled numerous antigenic double-stranded infectious environmental least Several well-deﬁned antigen-antibody hepatitis-associated antigenic subviral 22-nm spherical variable great nucleocapsid detectable conventional soluble high high undeﬁned recent detectable low clinical indistinguishable other acute viral incuba- average Clinical asymptomatic asymptomatic prodromal initial char- insidious abdominal upper icteric variable gray hepatic common other Most acute complete anti-HBs acute complete fulminant serious specific least asymptomatic fAnnual 1980-19 1-6 7-12 most Overall Higher early chronic chronic chronic many adult- chronic asymptomatic capable high hepatocellular active per- higher clinical epidemiologic clinical early sensitive infectious chronic serologic acute anti-HBc recent detectable best serologic negative positive single useful infective higher protective anti-HBs immune desig- positive appropriate milli-International protective effective chronic successful other infective other universal other insect 1-2 chronic positive chronic positive parenteral HBsAg-positive highest serous lower other such other unlikely percutaneous important other percutaneous other sharp instru- medical small overt needle such fresh cutaneous other important transmis- sexual heterosexual homo- sexual Fecal-oral homosexual asymptomatic sexual con- infective other direct mucous such hand-to-mouth hand-to-eye infective infective mucous environmental various other positive infected secondary active primary hepatocellular positive becom- infectious present present different global high chronic positive moderate HBsAg-positive low HBsAg-positive most early chronic greatest most asymptomatic little acute chronic high low reportable many reportable distinct serologic differ- available underreported due high asymptomatic anicteric l-6 Other ii intensive clinical serologic new late acute perinatal approxi- chronic common sexual heterosexual homo- sexual uncommon general certain lifestyle highest infected chronic high high 10-20 35-80 illicit parenteral 60-80 active 35-80 20-80 3-6 30-60 1-8 1-2 multiple 5-20 3-10 ﬁrst-time 3-5 available less optimal high available apparent uted several large Second major multiple active immuniza- public difficult preventive high low initial low infant plasma-derived due rapid high-risk low initial low comprehensive pregnant perinatal certain high plasma-derived puri- human safe effective unbased live other blood-borne human second similar common recombinant yeast- ﬁnal detectable infectious viral complete viral healthy adequate effective clinical complete normal protective high neces- sary other recommended certain table special Other ] 11-19 other four-dose antero-lateral immunoge- lower routine intramuscu- lar second third table new- highest last least ~~- 1-2 i 6-18 1-2 6-18 preferable 2-month other good other optimal HBsAf-Negative 1-2 6-18 1-2 6-18 oral same HBsAg-positive low Such low HBsAg-negative least full increased second second third percutaneous permucosal public blood-contaminated such highest recom- technol- other special behavioral medical high-risk other present effective susceptible active important possible homosexual high-risk trans- susceptible possible certain special such high sexual susceptible high unaccompanied high intermediate positive Other casual little vac- special such scratch- medical severe high certain such Alaskan endemic endemic such important susceptible house- susceptible high interfamilial Long-term due illegal homosexual high-risk active multiple sexual sexual previous close local sexual local common medical common high vaccine-induced intact signiﬁcant clinical en- anamnestic anti-HBs signiﬁcant docu- normal immune routine additional available annual intact anamnestic anti-HBs significant additional additional additional routine high endemic primary vaccina- adequate additional additional additional vacci- potential immune cost- effective such male cost-effective low such profes- routine vaccina- serologic recom- such suboptimal such occupational needlestick necessary deﬁnitive same other HBsAg-positive chronic HBeAg-positive same different available second third third oral diphtheria-tetanus- pediatric available table first different third dose feasible possible sexual age-appropriate HBsAg-positive HBsAg-negative anti- adequate positive dose anti- adequate sexual single last sexual last sexual sexual high-risk positive second primary higher old other identiﬁable such sexual common adverse systemic such Low-grade systemic adverse allergic prior Such allergic rare moderate such upper available pregnant severe chronic pregnant eligible such suboptimal 2°-8°C 35°-46°F frozen systemic young ethanol high anti-HBs anti-HBs passive percutaneous mucous sexual less old primary acute hepati- high-risk cold low low valid current unavailable Maternal American early unavailable positive sexual major inﬂu- clinical unencapsulated capsular cerebrospinal effective bacterial other invasive bacterial serious invasive gram-negative aerobic facultative accessory hemin- invasive m gram-negative responsible different a-f major distant responsible distinct capsular polysac- invasive several asymptomatic preva- normal uncom- Nontypable frequent human non-invasive unknown upper likely striking age-dependent 6-7 acquisi- humoral protective invasive geometric ug/mL postvaccina- unconjugated long-term invasive anticapsular natural 5-6 asymptomatic small common antigenic so-called anticapsular other genetic important genetic unknown single genetic convinc- many organ common invasive common clinical dis- mental stiff appropriate antimicro- bial life-threatening focal severe common invasive common invasive effective antimicrobial Ampiciliin-resistant common effective due nontypable invasive infectious pleural subcutaneous pleural viable available rapid sensitive specific capsular pleural similar sensitive difficult effective immedi- Ampicillin-resistant common life-threatening etiologic initial empiric deter- respiratory ﬁrm seasonal second contagious invasive certain particu- close day-care institutional second- ary able Serotype-speciﬁc most national several active dis- nationwide early oc- younger 40-50 late due vaccine-induced young Sept-Dec higher I-1 12-13 24-25 36-37 48-49 parental good unvaccinated age-dependent invasive 6-11 invasive invasive population-based 1976-1984 invasive Cumulative 59-141 98-197 10- 6-1 143-279 218-452 37-42 12-17 88-184 123-248 60-61 18-23 20-64 57-107 64-68 24-35 18-39 37-70 75-78 36-47 5-26 7-39 80-83 48-59 2-16 7-41 84-86 0-59 45-69 68-129 0.1-0.2 1.2-2.4 population-year active inﬂuenzae second expo- large house- low socioeconomic parental school-aged socioeconomic chronic breast-feeding maternal 1-60 invasive secondary higher general popula- secondary second third fourth secondary Most day-care low secondary effective younger efﬁ- negative greater available similar other polysaccharide pneumococcal meningo- typical T-independent age-dependent poor low-afﬁnity poor polysaccharide-protein polysac- poor effective polysaccha- T-independent young class- useful 1985-1988 effective older variable T-dependent active young different consis- immunogenic additional young dis- identical different available interchange- different primary immunogenic complete primary tered adequate 15-60 Alaskan months-5 efﬁca- cious high invasive protective nationwide immu- anu- ary DTP-Hib ten single-dose multidose available combina- combi- similar oral limited combined equal single primary separate acceptable unvaccinated chi-dren15-59 primary primary three-dose primary ACIP-Recommended 12-15 same primary optimal old minimum ” primary possible ﬁrst subsequent primary adequate protec- separate separate other other natural develop- protective anti-PRP invasive unimmunized possible invasive such sickle-cell human invasive 2-6 12-15 last -11 12-18 least last 12-14 unvaccinated 15-59 single 2-6 least substantial substantial advantageous early Alaskan least last -11 12-18 least last Unvaccinated unvaccinated 15-59 single unvaccinated 15-59 12-18 two- primary variable protective routine invasive unvacci- nated 2-6 least additional 12-15 least 6-month third separate ﬁve-dose primary same preferable Other unimmunized 2-6 12-15 12-18 dose 15-59 PRP-0MP 2-6 12-15 12-18 12-14 dose 15-59 PRP-D 15-59 same primary 2-6 elementary necessary fourth fourth uncommon and-or 12-24 such adverse local systemic similar concurrent individual due serious adverse moderate severe upper-respiratory same individual reportable invasive local primary invasive such vacci- immu- least and-or 5-30 adverse local acceptable due available / conju- more invasive single daily maximal < mg-kg daily day-care controversial less optimal necessary teratogenic possible more last prophy- likely same antimicro- invasive chemo- necessary discolora- soft ineffective- oral epidemic least “ Spanish inactivated protective single-stranded nuclear penetra- moderate such infectious viral least least 1918-1919 Single-stranded new same stable antigenic immunologic human subclinical epidemic geographic due sequential re- interpandemic serial irregular major antigenic protective anti- new major due genetic different wide major incomplete similar epithelial de- immu- nologic general classic clinical abrupt nonproductive 101°-102°F tracheal epithelial runny substernal ocular intestinal last more such be- rapid several most secondary bacterial inﬂuenza viral pneu- uncommon high demonstrable 5-10 1-5 nonproductive h primary secondary bacterial \ excess older epidemiological clinical compliment severe due possible other chronic pulmonary inﬂu- cardiopulmonary other chronic > inﬂuenza-associated inﬂuenza-associated older major 2- 5-fold severe sixth characteristic clinical nasopharyngeal per- amniotic 10-11-day-old certain viral additional local individual demonstra- significant inﬂuenza acute convalescent 10-14 human specific least 4-fold rapid diagnostic available clinic antiviral aerosolized important direct tropical 1-2 4-5 airborne 1-2 4-5 major 1889-1891 1918-1920 1957-1958 pandemic antigenic single high greater large severe fatal large Secondary tertiary 1-2 lower major high respiratory high early Secular clear excess different more excess several recent high case- high “ high-risk high-risk medical 2-fold 5-fold major popu- due epidemic esti- previous 5-year epidemic due con- secutive available available Whole-virus prepared zonal gradient inacti- prepared organic fewer adverse spatial viral useful whole- prohibitive effective clinical young healthy effective effective effective 1995-1996 live available next few single interpandemic recent minute practical inﬂuenza related prior vaccina- effective healthy young similar effective elderly effective clinical effective elderly effective effective 1982-1983 vaccinated effective more routine accessible undertaken mid-October mid-Novem- inﬂuenza 1995-1996 group-—United 6-35 annu- older least lower febrile split-virus puriﬁed-surface- split- whole-virus similar Other such intradermal ous topical unprimed older Other inﬂuenza vaccine resi- long-term chronic many pulmonary such chronic such congestive metabolic such f older long-term renal asthma influenza long-term high-risk essential influenza high-risk long-term house- high-risk likely elderly other outpatient high-risk provid- high-risk recent serious prudent protective anti- many low advanced essential institutional routine foreign previous high-risk current available his-her inﬂuenza high-risk pregnant medical reasonable theoretical undesirable pregnant high-risk common adverse follow- transient less Non-speciﬁc systemic recipi- previ- ous viral 6-12 last 1-2 immediate such allergic likely residual current small severe acute appropriate immunoglobu- other allergic similar medical inﬂuenza potential intradermal indicate local fﬂl nonexistent prior subsequent vac- other inﬂuenza adverse clinical attributable severe previous severe other medical safe pregnant undesir- able pregnant first higher high-risk epidemic- inﬂuenza-related older high previous least medi- cal previous less high-risk effective strate- episodic acute other residential long-term Acute-care hospital- high-risk hospital outpatient high-risk high-risk necessary on-site prior appropriate systematic automatic high-risk adverse unvaccinated poor severe influenza effective effective inﬂuenza house- high-risk antiviral replica- antiviral understood effective fewer effective adjunct late high-risk follow- unvaccinated high-risk poor inﬂuenza renal true other systemic due general referral likely susceptible high-risk medical alter- native epidemic con- high-risk protective unimmunized elective uncompli- influenza preva- new neces- sary related economic necessary rapid preventive unvaccinated high-risk regional less s nationwide weekly influenza new rapid preventive influenza-related economic low excess chronic effective 1987-1988 inﬂuenza sea- culture-conﬁrmed submit- depart- additional detailed other early wide-spread more other preventable ﬁrst pneumococcal other pneumococcal bacterial effective pneumococcal many antibiotic late pneumococcal pneumococcal lancet-shaped gram-positive facultative anaerobic short complex experimental capsular antigenic least identiﬁed other More Gram-positive important type-specific protective upper normal community-acquired hospital-acquired bacterial higher type-speciﬁc protective pneumococcal other additional common normal asymptomatic upper military many natural major clinical invasive pneumococcal pulmonary common clinical invasive pneumococcal pneumococcal short single uncommon Other common pleuritic rapid poor rapid pneumococcal community- hospital-acquired common bacterial much higher elderly pneumococcal pleural pneumococcal pneumococcal overall high elderly fulminant clinical pneumococcal pneumococcal pneumococcal clinical similar other bacterial nuchal cranial pneumococcal high elderly common pneumococcal pneumococcal other resistant speciﬁc pneumococcal infective effective higher elderly young bacterial elderly common other sterile available capsular lancet-shaped suggestive pneumococcal normal pneumococcal white epithelial 100-power gram-positive rapid clinical spinal pneumococcal positive large rapid diagnostic pneumococcal various spinal pleural highest spinal similar easier higher spinal rapid useful poor human asymptomatic direct person-to-person upper pneumococcal responsible such seasonal upper such pneumococcal high common early prevalent pneumococcal unknown reportable population-based invasive pneumococcal overall pneumococcal 15-19 older younger greatest pneumococcal invasive high 14-valent 23-valent capsular bacteremic pneumococcal additional available / pneumococcal highest medical older high-risk bacteremic pneumococcal highest young older older high older Community-acquired pneumococcal sporadic pulmonary Secondary pneumococcal common bacterial pneumococcal such invasive high pneumococcal capsular pneumococcal capsular different pneumococcal 23-valent pneumococcal pneumococcal bacteremic pneumococcal several capsular additional single pneumococcal signiﬁcant vaccine-type non-vaccine-type healthy pneumococcal poor significant pneumococcal various clinical effective invasive effective pneumococcal signiﬁcant effective normal such high severe older normal chronic cardiovascular pulmonary pneumococcal splenic surgical chronic renal nephrotic such organ asymptomatic symptomatic old older long-term high serious pneumococcal nephrotic asymptomatic symptomatic pneumococcal invasive effective normal immune chronic cardiovascular pulmonary splenic chronic renal nephrotic old splenic nephrotic old splenic nephrotic routine 14-valent 14-valent highest fatal pneumococcal high severe rapid nephrotic old rare healthy special social pneumococcal such certain Native American elective least two-week other immunosuppressive pneumococcal general available revaccinated Routine 14-valent 23-valent 14-valent highest fatal pneumococcal highest 23-valent rapid pneumococcal nephrotic nephrotic old such pneumococcal severe local such severe allergic serious allergic pneumococcal Such allergic rare moderate such upper pneumococcal healthy pregnant high pneumococcal pneumococcal pneumococcal same different pneumococcal highest pneumococcal older other serious pneumococcal high pneumococcal subsequent high signiﬁcant pneumococcal illness severe pneumococcal 3-5 common preventable older low recog- nized infectious vesicular susceptible vesicular healthy other primary latent regional primary 4-6 other such viral regional 14-16 10-21 1-2 2-4 pruritic secondary viral Clinical varicella pruritic highest mucous clear erythematous several present several macular same successive clinical normal severe higher gastrointestinal severe progressive high extensive vesicular high prolonged primary healthy clinical other viral natural wild clinical detectable young skin central nervous pulmonary hepatic extramedullary cranial cranial few systemic Post-herpetic available Post-herpetic last other severe mild self-limited common secondary bacterial skin central nervous common outpatient medical serious viral bacterial common healthy fatal viral bacterial maternal 1-14 15-19 20-29 nervous aseptic common good infrequent cerebral common unusual unknown dramatic aseptic hemorrhagic clinical healthy normal healthy higher high serious high organ fulminant pneumonia maternal overwhelming high severe fetal passive maternal prior due passive maternal low cicatricial muscular cortical congenital primary maternal low congenital maternal virologic maternal earlier exact unknown useful necessary necessary vesicular vesicular giant consistent vesicular ﬂuorescent monoclonal sensitive low small clinical standard endemic 1-2 4-5 reliable valid distinctive subclinical unusual necessary useful available Available indirect indirect immune latex enzyme-linked sensitive unsuitable general diagnostic least sensitive sensitive available available sensitive rapid sensitive commercial useful acute signiﬁcant single positive occur common human insect common infected airborne direct acute distinct seasonal highest early highest lowest tropical seasonal contagious entire new contagious contagious more Secondary susceptible high Secular endemic notiﬁable 10-14 15-10 20-20 less highest age-speciﬁc notiﬁable occur least live attenuated viral early healthy sequential human embryonic human general healthy clinical detectable least Japanese healthy clinical second least second clinical clinical fewer many maculopapular Most 7-10 Routine 12-18 prior necessary reliable safe effective healthy same separate separate same least separate separate other other susceptible reliable susceptible severe frequent current much susceptible More immune effective healthy single least healthy detectable single older second reliable immune acceptable physician necessary reliable uncertain susceptible such clinical reliable personal reliable susceptible reliable immune likely effective prior susceptible susceptible desirable higher likely highest susceptible high serious susceptible susceptible high such young institutional correctional military susceptible international reliable likely effective necessary seropositive second potential full possible detectable unlikely 5-6 anamnestic present susceptible negative high severe Susceptible high severe young institutional Military international susceptible effective necessary low susceptible low susceptible potential vaccine-associated high serious such Post-exposure post-exposure current additional available unvaccinated susceptible protective unknown susceptible Adverse common adverse such clinical local second local mild self-limited varicella-like second varicella-like second Most maculopapular live similar wild 4-5 similar due wild post-herpetic similar other severe allergic minute ill potential such such upper antibiotic other active due immune immunosuppressive low topical immunosuppressive chemotherapeutic available > 4-5 frequent natural severe 1-800-986-8999 special certain acute lymphoblastic further asymptomatic symptomatic human asymptomatic inadvertent HIV-infected clinical unknown wild small lower deﬁnitive pregnant insert American maternal-fetal pregnant 1-800-986-8999 antibody-containing immune whole red intravenous unknown potential least antibody-containing such seronegative healthy potential susceptible higher susceptible secondary clinical frozen average frost-free last 5-10 low acceptable unsealed uninsulated small dormitory-style capable preservative other anti-viral short separate 1-800-9VARIVAX 1-800-982-7482 short possible secondary clinical asymptomatic susceptible acceptable 1-800-9VARIVAX 1-aoo-9s2-74a2 pregnant central off-site more higher-than-recommended available such off-site off-site dry appropriate human high available clinical susceptible negative greater general expensive temporary susceptible high continuous same 2- 4-bed direct immune neoplastic immunosuppressive less gram adequate maternal immune such susceptible pregnant possible longer detailed signiﬁcant direct maternal hospitalized entire synthetic human available early healthy beneﬁcial new cutaneous systemic non-pregnant chronic cutaneous pulmonary short immunocompromised viral-mediated Most school-aged American healthy sufficient normal more severe secondary cutaneous pulmonary short intravenous possible Minimum initial reliable indicate acceptable 4-6 11-12 14-16 lDTaP American American HBsAg-negative HBsAg-positive separate 1-2 unknown 11-12 year-old least least least least acellular least last primary immunosuppressive acceptable other primary 3-dose minimum 4-6 11-12 susceptible reliable 11-12 year-old infant-Adolescent mug-05ml same same same same l- available appropriate immune various live units/10kg 20-40 negligible i0 l0 humoral immune 300-400 mg-kg mg-kg ‘ mg-kg grams-kg entire additional and-or particular immune idiopathic thrombocytopenic initial first minimum roble current accelerated fourth least i5 fourth fifth 4-6 elementary least fourth total eoch §The American high least previous * conventional unvaccinated < available least young i2-l5 local other measles-containing least final Table RR-1 “ im- inclusive serial Vaccine-Preventable infectious Other philia such antibody-containing such human active passive immuni- live im- infectious complex live li- censed bacterial sterile human large intramuscular certain immunodeficient passive other infectious similar suitable intravenous infectious primary im- chronic lymphocytic intravenous high specific immune infectious specific specific passive Table smallpox physical admin- inclusive active passive other immune temporary passive human immune ref- active synonomous devel- adequate chil- third oral measles-mumps-rubella 12- Other new other available proper dis- immune live simultaneous multiple vac- different pre- lm- new docu- vaccine-preventable available comprehensive Additional other pur- char- scientific active passive public clinical safe effective partial asymptomatic such common minor severe life-threatening scientific optimal infectious im- other relative theoretical related gen- eral most military certain specific immunobi- same infectious different active various same familiar complex other serum cell-culture-derived pre- bacterial viral final sensitive suboptimal immunologic such / im- respon- general such oral yellow sensitive Other sensitive acellular pneumococcal appropriate necessary recom- new infectious open sterile disposable separate same such nee- labeled puncture-proof unnecessary local systemic optimal lnjectable little local neural vascular general lo- same adminis- PRP-T/DTP available Subcutaneous Diphtheria-tetanus-acellular Japanese oral parenteral whole whole bacterial bacterial viral whole pneumococcal lntradermai/percutaneous intramuscular subcutaneous tAvailable intradermal lower subcutaneous specific intradermal human lower intramuscular same smaller acetone-killed available special certain pediatric lymphocytic available available intravenous intravenous immune human human human human human human pre- thrombocytopenic chronic lymphocytic human human post- susceptible immunocompromised certain susceptible pregnant newborn other- intramuscular needle new older 5/8- 3/4-inch 23- 25-gauge dermal intramuscular anterolateral upper upper active potential inadvertent subcutaneous deep passive large vol- necessary large immune central upper perpendicular sciatic subcutaneous neurovascular familiar structural vac- individual needle in- anterolateral largest multiple same 7/8- l-inch 22- 25-gauge sufficient 4-month-old free nearby neurovascular Older ade- needle anterolateral needle intradermal volar fore- severe deltoid 3/8- 3/4-inch 25- 27-gauge long entire small small intradermal suboptimal immunologic more immune preferable different anatomic preferable intra- muscular same more single preferred greater 1-2 local unlikely same mul- many same short safe effec- comparable needle potential bloodborne-disease potential dis- sub- potential greater such human other certain large same practical and-or local public small po- tential bloodborne-disease potential other mathematical animal potential bloodborne-disease transmis- stationary advisable local disposable nozzle potential bloodborne oral oral vac- substantial 5-10 same re-administered next theoretical experimental clinical inadequate protec- deltoid intramus- smaller such inadequate larger hazardous excessive local other full smaller serologic clinical such ade- less standard documented nonstandard relevant se- several age-specific age-specific active 1-2 6-18 12-15 live seventh early available early previous least tetanus acellular fourth and-or seventh American 6-18 second junior high 12-15 first newborn first other routine HBsAg-positive possible same and-or late appropriate 12-15 second third third through-out Diphtheria-tetanus-acellular live 12-15 specific available fourth and-or seventh primary additional 12-15 least previous 7-11 primary PRP-OMP-containing additional 12-18 least previous 12-14 primary PRP-OMP-containing additional previous fifth special early Second 6-8 prior specific immune nonpregnant * high-risk occupational such health-care certain active homosexual bisexual certain active heterosexual long-term certain international HBsAg-positive endemic universal and-or common second measles-containing certain live first live measles-containing least physician-diagnosed post-high educational direct endemic second live individual po- tential maternal general youngest adequate periodic multiple satisfactory Longer-than-recommended final entire minimum recommended minimum in- primary local certain Such Good careful such Simultaneous extensive clinical scientific certain 13-16 Many simultane- same same anatomic important certain several infectious foreign further general separate local systemic feasible preferable separate simultaneous live impaired similar individual different medical oral live theoreti- immune live oral oral live same international short no- other important im- appropriate recent unvaccinated chil- same simultaneous same separate similar acceptable 14-16 simultaneous specific complete vaccina- different different important subsequent 12-15 acceptable other health-care likely ofthese fourth fifth seventh individual same same adminis- Other simultaneous pneumococcal whole-virus satisfactory increas- adverse pneumococcal split-virus ex- yellow safe effica- cious yellow full yellow admin- short other possible yellow least necessary simultane- 3-week optimal many effec- substantial limited dura- few antimalarial immune re- oral live typhoid vac- least other related such intradermal intradermal other 24-26 other certain yellow general different live limited anti-PRP certain 27-29 prior live-virus available possible live- different least Table other Live-virus 32-34 same live-virus 4-6 specific hepa- immune oral low immune individual early recent high immune globu- immune immune unknown commercial whole red other antibody- specific intravenous immune individual after-an rubella-susceptible other last live minimum live doses.f 4-week minimum oral possible local systemic parenteral separate least yellow adminis- other optimal §lf oral live international short minimum interval different live simultaneous measles-mumps-rubella unavoidable different related large such specific intravenous immune whole red yellow oral immune globulin-containing immune monovalent dose-related possible least necessary immune necessary imminent admin- immune immune necessary various live units-10 20-40 negligible 80-100 humoral immune 300-400 mg-kg mg-kg mg-kg grams-kg entire additional and-or particular immune congenital idiopathic thrombocytopenic 1-2 subsequent serologic immune live inactivated immune protective immune adminis- different indi- least subsequent different comparable full single efficacious safe able full 1.0-mL different single various live influenzae different temporal immunologic sequential different satisfactory complete primary 43-45 primary same feasible different adequate recommended 12-18 allergic reac- local systemic mild anaphylactic-like responsible common yellow able anaphylactic anaphylactic-like adverse able allergic yellow anaphylactic 46-49 regi- severe human severe pa- hypersensitive such hy- individual skin anaphylactic Most neomycin contact dermatitis-a delayed-type cell-mediated immune delayed-type parenteral such local systemic such sore- difficult specific toxic Urticarial anaphy- lactic appropriate deter- preservative Japanese intradermal indicate local delayed-type same chronological same full- stable pre- 54-56 full theoretical de- HBsAgl-positive HBsAg-negative optimal low Such low HBsAg-negative least live affect contrain- 59-61 special breast-feeding live yellow theoretical pregnant potential high unlikely lmmunobiologic rou- susceptible pregnant last primary required three-dose necessary other recom- pneumococcal pneumococcal pregnant substantial immi- nent natural complete yellow small theoretical yellow vac- theoretical attributable susceptible pregnant live first admin- pregnant susceptible passive pregnant available American available specific immunocompromised individual additional large live 65-71 general certain immunocompromised other close immunocompromised serious unusual severe per- asymptomatic HIV-infected symptomatic HIV-infected HIV-infected regular individual ac- quired potential next monthly unlikely serologic specific additional routine ther- such suboptimal such usual certain such pneumococcal certain immunocompromised functional anatomic poor immunosuppressive least live-virus exact ad- healthy steroid contraindi- live short low long-term alternate-day short-acting intra-articular recent severe such ther- immunosuppressive many greater least dis- live-virus high such ac- least same general other vaccine-preventable in- subcutaneous intradermal adminis- intramuscular 23-gauge steady more local such low other intramuscular familiar reasonable other similar such fine least health-care certain circum- true true adverse true applicable anaphylactic anaphylactic-like previous severe local injectable low-grade antimicrobial same normal full-term infectious other such previous prior hypotonic-hyporesponsive prior inconsolable previous sudden syndrome adverse solid congenital long-term immunosuppressive antimicrobial solid congenital long-term immunosuppressive common more detailed specific individual foreign neurologic individual prudent theoretical immediate full imminent personal theoretical other anaphylactic such [ 102:196-9 lf postponed-for 4-6 altered theoretical pregnant true ad- prior inconsolable shock-like previous important minor upper- local previous current antimicrobial current recent feb- such mild upper-respiratory low-grade other low-grade minor 74-76 medical important Most effi- 77-79 large more mild lower minor upper-respiratory mild other moderate febrile acute super- adverse Routine physical healthy moderate appro- safe effective adverse minor local severe such impossible cause- and-effect temporal unvaccinated necessary rious adverse important adverse complete adverse specific other health-care adverse other other serious unusual available ’ 24-hour effective civil traditional first substantial eligible ditional available 8-05 legal understandable Op- informa- allpublic private private own Such available individual responsible important public other set- responsible similar private toxoid vaccine-preventable such adverse medical permanent medical permanent health-care private public includ- federal local important parental permanent many new computerized adequate docu- previous such susceptible influenza adverse serious adverse further most local similar initial other adequate documenta- reliable local inter- national reasonable other adequate comparable follow- current initial dose weeks§ primary Diphtheria-fetanus-acellular oral acceptable current accelerated fourth least primary fourth fifth elementary least fourth total seventh §The high least previous * conventional unvaccinated < available least young first 12-15 additional local other measles-containing least final earlier / acceptable op- valid Self-reported different important developing sero- lower 12-15 first 12- local high other measles-containing least Chil- primary first same polio-endemic extra valid primary available first least least second third conventional available primary first least least third fourth inactivated enhanced minimum valid vaccina- many more additional current valid first fourth adminis- less third previous first early least final third fourth least previous preferable recommended valid Specific require- different best vaccine-preventable important good intensive physi- appropriate available appropriate private immuni- conducive unnecessary elimi- adverse addi- appropriate primary diph- medical pneumococcal serious pneumococcal vac- annual possible susceptible other post- high educational high health-care trav- endemic other other young single other different widespread high-risk high health-care immuni- necessary as- vaccine-preventable such appropriate institutional such primary appropriate correct Such health-care at-risk other such VACCINE-PREVENTABLE prompt vaccine-preventable local health-care vaccine-preventable vaccine-preventable notifiable individ- ual local local other unusual national general other available specific Official Manufacturer-provided product-specific infor- weekly special specific available available national specific foreign address in- ternational specific communicable pre- specific and-or available 24-hour next individual immuniza- American available American manual manual infectious up-to-date other con- available healthy available new edi- important available many local technical other educational 24-hour in- technical preventable various further tional 38:205—14,219-27 man- lymphocytic French sciatic 58:195-204 anatomic immune 7:425-30 Intramuscular 18-month-old in- thigh 10:455-60 lpp needle comprehensive universal testing-United measles-mumps- other preven- tive meningococcal measles-mumps-rubella oral 14- 23-month-old simultaneous recombinant multiple live oral unvaccinated preschool- Simultaneous pneumococcal 247:2551-4 oral live 1989:248-53 typhi oral pre-exposure human 314:280-4 Pre-exposure human coun- 34:633-47. capsular polysaccharide-protein 45:582-91 infant 29:10-3 11:846-51 diph- endogenous 1965:2:401-5 tuberculin 270:386-91 live viral 55:392-6 live 274:67-72 immune oral yellow 62:585-90 immune clinical infectious systemic local 162:1291-7 ofmixed primary preliminary ] live egg-allergic 263:269-71 Safe mumps-measles-rubella egg-allergic 13:504-6 pa- hypersensitive 102:196-9 asthmatic hy- 106:931-3 24:6-10 preterm diphtheria-tetanus- 107:184-8 diphtheria-tetanus-pertussis oral 103:917-9 Half-dose pre-term preterm breast-feeding 248:2451-2 oral 13:926-39 Hahn-Zoric parenteral oral conventional low-protein vaccine- supplementary 36:795-8 yellow immu- 168:1520-3 2:79-114 Vaccine-associated sex-linked 128:802-6 progressive secondary 297:241-5 34:227-8 63:1268-9 military human 316:673-6 intramuscular 300:1694-5 pediatric 42:1-13 112:540-6 parental 12-month 142:283-6 op- public old maternal ill ill preschool-aged crobial mea- sles-mumps-rubella 265:2095-6 40:726-7 acellular use— supplementary acellular fourth fifth supplementary public preventable 39:725-9 available weekly provisional weekly national public special immune current active acces- sible single individual marrow trans- separate Other different rec- appropriate higher first brief vaccinat- immunocompromised second specific immuno- third immunocompromised final due congenital human large affected such due immunocompromised specific such higher certain additional bacterial pneumococcal meningococcal good higher frequent suboptimal such short low long-term alternate-day short-acting infra-articular exact systemic healthy immunosuppressive many immunosuppressive live-virus greater least discon- live-virus high-dose systemic practical immune renal special higher particular Non-HIV-lnfected congenital immunodefi- large 1-3 admini- live 4-6 general live contraindi- close least live-virus immunosuppressive organ suboptimal immunosuppressive unim- least Passive immune vaccine-preventable such susceptible HIV-Infected general live-bacteria vac- asymptomatic necessary asymptomatic symptomatic serious unusual adverse preferred routine higher non-HlV-infected severe general symptomatic suboptimal immunologic re- live higher HIV-infected higher frequent medical such renal alcoholic certain bacterial such immune good higher fre- routine usual renal particu- pneumococcal lower secondary primary progressive important chronic immunosuppressive renal pneumococcal several immunologic abnormal dia- betic little clinical cardiovascular renal other end-organ one-time pneumococcal annual coccal safe effective oral antidiabetic diabetic Such many clinical im- uncertain chemotactic cell-mediated cirrhotic portosystemic alcoholic one-time pneumococcal yearly functional fulminant bactere- high pneumococcal asplenic pneumococcal meningococcal asplenic same other- healthy immunogenic elective pneumococcal meningococcal least possible symptomatic eligible infec- asymptomatic necessary asymptomatic symptomatic serious unusual adverse single-antigen 6-11 symptomatic HIV-infected prior immunocompromised maximum < such such unable severe progres- sive neurologic 29-32 safe protec- maxi- other such immune other harmful asymptomatic asymptomatic necessary live-virus tubercu- negative high untreated infectious pulmonary long-term preventive resistant tuberculin-negative new usual feasible limited safe asymptomatic recom- HIV-infected symptomatic further high HIV-infected per- preventive inactivated alternative severe immuno- such yellow necessary potential possible such effective non-HIV-infected desirable be- appropriate 303-221-6400 yellow laboratory orthopox certain health-care clinical symptomatic military immunocompromised same immunocompetent acellular specific pertus- available immunosuppressive reasonable least last received 0th- other unvaccinated primary enhanced-potency immu- normal immunocompromised same specifi- anatomic functional undergone insufficient immu- other immunosuppressive more HIV-infected individual higher HIV-infected non-HlV-infected severe least possible pneumococcal meningococcal separate different serious per- protective many sympto- matic low HIV-related im- little influenza HIV-infected chronic renal annual adequate 41-43 renal prophy- aman- renal pneumococcal anatomic functional nephrotic cerebrospinal nephrotic old pneumococcal chronic cardiovascular pulmonary pneumococ- cal splenic anatomic chronic renal nephrotic such organ first highest fatal pneumococcal asplenic highest rapid chronic renal nephrotic susceptible serore- lower healthy frequent renal likely Such higher serocon- periodic necessary successful serologic 12-month other immunosuppressed higher special avail- able such impaired higher unknown firm anti-Hbs such 1-3 additional certain high-risk terminal anatomic functional acceptable meningococcal vac- clinical other immunosuppressive immunosuppressive active immunosuppressive un- essential other other immunosuppressive im- Other Other immunocompromised same immu- normal passive exposed passive immuni- possible symptomatic other previous effective such immunocompromised maximum mg-kg necessary 100-400 last similar high-dose effective available mg-kg humoral same important susceptible immunocompromised significant close same two- prolonged direct such immunocompromised lower Varicella-susceptible serious general especial first pregnant susceptible unknown immunocompromised susceptible likely negligible substantial experienced immune impractical protective same perinatal needle- sexual positive same same same immunocompromised 4:123-42 responsible adverse severe immu- disseminated American vaccine-preventable human prospective population-based 116:806-—12 268:3350-2 pneumococcal HIV-infected bacterial human pneumococcal HIV-infected homosexual 257:2047-50 pneumococcal asymptomatic heterosexual intravenous human 160:826-31 HIV-infected 162:238-41 12:481-4 renal 22:434-46 pneumococcal renal ofdialysis-associated 153:1149-51 chronic renal renal 20:254-8 pneumococcal renal hemodia- 141:1637-40 renal 182:468-73 renal pneumococcal 146:1554-6 pneumococcal poly- 244:2621-4 267:1237-41 2:79-114 Vaccine-associated sex-linked agam- 128:802-6 progressive secondary immunodeficient 297:241-5 63:40-1 human immu- 34:227-8 63:1268-9 military human immu- 316:673-6 immunosuppressed human humoral cell-mediated influenza 33:21-5 chronic renal chronic renal 14:614-8 influenza renal 40:421-4 immune renal 42:376-9 pneumococcal high-risk chronic 1985:5-6 chronic renal 157:332-7 undergoing human subop- timal 109:101-5 routine medical medical immunosup- inactivated human human immune oral non-HIV Other congenital aplastic large organ immuno- chronic lmmuno- immunosuppressive infection-AIDS alcoholic indicated indicated indicated indicated indicated large renal anti-Hbs organ chronic renal immunosuppressive infection-AIDS non-HIV inactivated congenital aplastic large symptomatic susceptible susceptible significant significant susceptible pre-term susceptible pregnant non-immuno- serious non-immuno- susceptible percutaneous sexual non-immuno- post-exposure congenital aplastic large old next old old old short-course many other old old last v 57-60 Vaccine-Preventable diseases- per- paralytic public most substantial provisional pre- provisional provisional final fewer longest such diph- age-specific inva- invasive preschool-aged preschool-aged vaccine- preventable lowest asymptomatic likely chronic acute vac- achiev- high low 1981-1988 1989- measles-attributed preschool-aged unpublished national 11- second unaccept- low many comprehensive national indigenous vaccine-preventable least 2-year-old Table high preventable routine 1992-1993 provisional available available llnvasive asymptomatic chronic conﬁrmed vaccine-associated broad local new federal clinic health-care health-care ad- due health-care long-term national health-care health-care national widespread public national other public pri- voluntary religious vaccina- public eligible American able free additional federal measur- ing national local young undervaccinated 3-4 3-4 available * ofﬁce-based as- health-care vaccine-prevent- able en- able aggressive and-strengthen Many-federal educa- other assistance-to high many private new new effective monthly preventable routine previous provisional provisional primary preschool 1:315-30 269:221-6 pertussis-United 42:952-3,959-60. rec- 266:1547-52 2-year-old 1991-1992 42:985-8. pediatric 269:1817-22 American Other comprehensive ultimate best primary Overall primary intensive many vulnerable preschool-aged due clinic present user-friendly family-centered sensitive comprehensive rapid efficient consumer-oriented recent measles-related other vaccine-preventable pediatric public private desirable possible own necessary useful additional available unnecessary available free minimal clinical general true eligible accurate complete other adverse semi-annual up-to-date retrievable medical patient-oriented community-based current available responsive large urban public available daily smaller rural many other same primary Ready unnecessary public private available walk-in routine new available other comprehensive such primary appoint- physical reliable guardian assess- general guardian potential public dependent individual referral available free minimal free private reasonable Affordable greatest private consolidated federal clinical eligible and-or particular other general sensitive own s full appropriate educational suitable specific acceptable possible adverse prior federal own alternative other public private current available appropriate satisfactory medical day- night- adverse true true true true more detailed American eligible Available simultaneous safe effective simultaneous such automatic routine complete personal personal new previous prior former regular manual separate retrievable inactive separate primary other other other such dental such adverse legal such signiﬁcant available 1-800-822-7 adverse medical possible 300aa-25 overdue manual additional intensive high local public semi-annual private pre- school-aged up-to-date second simultaneous such ongoing up-to-date retrievable medical appropriate possible adverse Such necessary medical medical familiar patient-oriented necessary more user-friendly community-based high active Such community-based public local high high vaccine-preventable highest possible trained appropriate other administer and-or create legal necessary current current other such national complete local severe low-grade antimicrobial same normal full-term infectious other such previous previous prior stale hypolonic- sudden prior personal inconsolable :3 prior solid long antimicrobial immunosuppressive positive solid immunosuppressive individual foreign neurologic individual prudent theoretical immediate personal theoretical multiple live same suboptimal anaphylactic such 102:196-9 113:504-6 more detailed s. new older preventable infectious pneumococcal older pneumococcal certain high Most older inﬂuenza-related new other such Pneumococcal common serious pneumococcal other Pneumococcal most other necessary 20007-3835 Elderly rib-W 582-416/20025 educational motivational efﬁcient public private national other other general primary safe effective available influenza pneumococcal more American several last local public professional private other public vaccine-preventable national pragmatic common disease-speciﬁc informational educational current local-based pneumococcal broad-based similar private public different local promotional pneumococcal primary two-dose special high-risk post-secondary international major high high legal primary post-secondary vaccine-preventable current higher educational own dependent realistic reasonable cost-effective open many Several classic recent congenital constant unhesitating vaccine-preventable fewer vaccine-preventable pneumococcal overall other vaccine-preventable vaccine-preventable different different universal few private complex new pneumococcal recent Many federal active several greater vaccine- major complex substantial general vaccine-preventable important such bad good large informational regular Eﬁ'ecrive vaccine-preventable efﬁcacious effective responsible other vaccine-preventable major recent adequate essential strong local major special many other federal federal local primary general other private partial ﬁnancial federal local recent pneumococcal inexpensive cost-effective other adequate public private private national vaccine-preventable assured periodic 1989-1991 important large urban effective black available sole able enough certain second vaccine-preventable eﬁective current vaccine-preventable new new extensive public private other better vaccine-preventable vaccine-preventable ﬁmdamenral continued clinical available adequate greater several available other preventable new stable other pneumococcal such preliminary such pneumococcal provisional Overall high-risk lower attributable preventive medical such pneumococcal 44:506- 7,513-5 pneumococcal collaborative pneumococcal collaborative technical State-based inﬂuenza statewide target- few 1995-96 other 1996-97 annual national other preventive technical pneumococcal 1989-1993 technical long-term action-based technical technical community-based older pneumococcal pneumococcal computer-based pneumococcal pneumococcal technical successful inﬂuenza many many preventable young ll-l2 early other advisory routine other certain several initial important other preventive national advisory other preventive young Table American specific comprehensive preventive other American various preventive regular biomedical behavioral emotional compatible other adolescent preventive consistent initial initial primary 14-16 previous dose second adolescent reliable underlying medical high-risk pneumococcal high intermediate high endemic subsequent three-dose Other preventive other preventable diseases-—United 43:7l8-20 pediatric Red American 1994:64-5 infectious Green ll-2l 1994:195-257 clinical periodic many vaccine-preventable pneumococcal vaccinepreventable pneumococcal young 1985-90 safe effective available high medical previous least outpatient serious pneumococcal least previous pneumococcal appropriate other complete high-risk annual other appropriate prior other higher other medical appropriate vaccine- preventable health-care third-party governmental health-care standard personal institutional lntemal public private educational motivational efficient public private national preventable major safe available Several low inadequate aware- medical public private federal major public major clinical financial public private vaccine-preventable dis- vaccine-preventable new prac- international many infec- tious disap- whoop- indig- enous few congenital ru- sel- re- extraordinary attributable widespread congenital syn- vaccine-prevent- able constant complete 1994-Vol 272:1133-1137 vaccine-preventable strik- fewer vaccine-prevent- able compari- inﬂu- pneumococcal hepa- many child- vaccine-preventable young major such Vaccine-preventable main important costly American several ad- much heavier dis- Table Several ex- limited per- general vaccine-preventable signiﬁ- cant efﬁ- several immuniza- selective universal different individual larger child- child- statutory communi- few private ne- private in- expensive free most full public avail- responsible high best diﬁi- same new pneumococcal vac- many new ini- fectious next inﬂuenza cost- vaccine-Preventable 1964-1965 available provisional vaccine-undated reportable Table minim-.6 mlqhlyvanable applicable irn- Vaccine-preventable signiﬁcant strong cost-eﬂ'ective more un- less ﬁrst new under- able clinical good organiza- vac- de- successful regular public se- vaccine-preventable general high-risk immu- pneumococcal severe Most elderly pneumococcal young sexual ac- Many un- clinical irnmuniza- admin- helpful older educa- tional other wide- spread rec- pe- riodic immu- better understand- administrative organiza- tional successful profes- devotedto prac- tical vaccine-preventable dis- ben- easy vac- recom- educational espe- announce- popu- emcacious eﬂ'ective public federal con- epidemiol- vaccine-preventable pro- lrmunization-The regular stan- regular evalu- ﬁnancial federal local pneu- mococcal local unpublished pneumococcal vacci- elderly reim- end- renal inﬂuenza reim- mea- pneumococ- pneu- mococcal nationwide-could pro- adequate important apparent annual little ex- private im- organi- such bet- Table lnf'luena 18-24 25-64 detailed high-risk medical occu- environmental foreign postsecondary educational international vaccine-prevent- able Such vaccina- several mis- vac- vaccine-preventable due vac- high Most ad- wide principal general spe- profession- administrative such such single respon- workable of- Such common other federal vaccine local corn- administra- tive organizational 1994-V0l ditional regulatory private im- sufﬁcient subject gov- Similar reimburse administra- moni- ﬁscal iden- technical ﬁnancial other private reimburse indi- vidual cov- public effective vaccine-preventable adequate local adequate such national vaccine- adequate vaccine-preventable clinical international insured national pro- immu- vaccine- preventable continu- them- capac- periodic vac- effective efﬁcient vac- clear un- epi- important per- local vaccine-preventable ex- timely ad- current protective under- hepati- pneumococcal inexpensive rapid essential economic vac- cine-preventable immuniza- constant pro- economic vac- es- costly pneumococcal 1994-Vol elderly pneumococcal little geographic great vac- other surveil~ vaccine-preventable local better recom- current future peri- potential technical regulatory ﬁnancial legal political appropriate federal related speciﬁc high-risk condi- speciﬁc pro- un- fol- pneumococcal institution- ill older least pneumococcal inﬂuenza non- high-risk least high-risk antigen-positive least work- least intravenous-drug us- least homosexual bac- essential new vac- important vaccina- older immune responsive ef- clinical serious costly economic vaccinepreventable dis- im- cur- pneumococcal other pre- inter- common elderly epi- vaccine-preventable vac- provid- recent greatest likely several new cold-adapted live pneumococcal acellular new newer adju- epitope-based re- rec- immunologic vaccine-pre- veritable other international such other infectious such former new antimicrobial-resistant many coun- rich eradi- new be- new vac- new continued microbiologi- cal vaccine-preventable immunocompromised de- better economic cur- future vaccine-preventable dis- irnmuniza- evi- current fu- recom- greater stud- new stable com- greater federal nongoverrunen- tal professional associa- interna- tional 327:1794-1800 recommen- teta- other 40-No RR-IOhI-E. Eradi- 10:222-229 1989- 43:451-463 congenital 267:2616-2620 univer- in- 1987-1993 43:144-148 267:392-396 Reportable vaccine-preventable 43:57-60 328:1252-1258. medical set- em- 1994-Vol complex sub- stantial irnmuni- op- timal infectious im- optimal adverse responsible non- produc- assistant seu-etary Ne- im- elderly 153:2106-2111 l-vi 1-94 public preventable 39:725-729 demon- 8-1992 42:601-604 pub- pneumococcal elderly 1993:109-113 108:616-626 inﬂu- enn mem- public Vine-ent Syl- computer-generated vac- RR-9 alternative 263:1218-1222 Pneumococcal poly- cur- 270:1826-1831 1978:48-66 79-81 140:5E-530 1986-1992 42:768-770 Russian 1990- blow-tal 42- 840-841 toxigenic 501-503 drug-resistant pneumococcal 271:1831-1835 live strain-8/70 RIT-SmithKline live live German further live 7-73-MSD further strain-live mumps-live live immunoglobulin-Swiss strain-7/7l strain-8H8 oral killed-inactivated SmithKline-RIT Swiss 27-3M T-Immun attenuated-Schwartz strain-Perum oral Swiss 881-5600 Pharmaceutical 288-8370 533-5899 595-7372 572-8221 insulated 2°-8°C 35°-46°F direct frozen 2°-8°C 35°-46°F vial vial frozen Stable 2°-8°C 35°-46°Fl shortest __ dry cold-below 46°Fl-refreeze free- warm-above 46°Fl-or lower freeze-thaw ble total cumulative using-may unopened 2°-8°C 35°-46°F freeze-thaw permissible provid- total cumulative tempera- red pH usual dry due low possible live less dry tem- warm Vaccine-refrigerate immedi- 2°-8°C 35°-46°F such 59°-86°F Special con- inject thor- entire total vial vac- 10-Dose separate sterile 50-Dose 35°-46°F Special shortest 10-Dose injec- needle 50-Dose utilized needle live frozen 2°-8°C 35°-46°F vial frozen vial Special frozen 2°-8°C 35°-46°Fl lower such immersed shortest clear shortest possible excessive frozen 2°-8°C 35°-46°F current vial Special shortest Td- Tetanus-Diphtheria 2°-8°C 35°-46°F direct frozen 2°-8°C vial re- frozen 2°-8°C vial withdraw- Special shortest lntrader- severe local electrical electrical electrical expensive typical oral short-dated stable big last correct old healthy pregnant minimum next old young prior 8-week available subsequent old high additional certain high community-wide beneficial additional 5- old — short-course many complete dose other Short-course aerosol anaphylactic egg-containing whole old immunosuppressive second old last § effective such such legal such such visual oral appropriate other legal permanent medical legal additional applicable camera-ready available new new original lengthy legal covered legal other individual such other relevant public grammatical typographical new public private own own new Camera-ready a-ll responsible public single camera-ready metro private camera-ready camera-ready camera-ready p-o-t legal available inﬂuenzae permanent medical federal appropriate legal other permanent medical medical legal other informed procedural substantive informed oral informed new easier table health-care several neurological serious local other modiﬁed same own federal federal available available available other available other available other Armenian Cambodian available many private pro- public private appropriate new hood- sim- mate- legis- original lengthy re- presi- de- mate- legal covered vac- legal other easier shorter attractive inch white pa- previ- ous 5th-7th com- specific le- other individual par- ticular ben- such other relevant own ﬂex- own old new re- sponsible distribut- public clin- Camera-ready explanatory single camera-ready cop- metro in- pri- camera-ready de- l2-la mam-oreg- om-Mal local other addi- prior them- camera-ready legal representa- permanent medical pro- permanent medical num- adminis- nese French available tant same own re- administer- manufactur- federal federal combina- diph- serious serious painful best many fewer dis- rare acellular many more older least vac- third Other same serious other other moderate severe pregnant sure small serious get- smaller serious last l-2 non-aspirin serious allergic upper many 30000-26 toll-free toll-free more She-he other serious u serious painful several hard Other same best most many fewer many more gcellular likely likely moderate Most young serious other severe worse sure small serious smaller other serious last i-2 less appetite non-aspirin important § 30000-26 higher unusual high-pitched serious decreased rare serious toll-free toll-free more She-he other German serious » spinal such painful other serious best most many fewer many more i/ l2-l 4-o middle junior high Other same young able serious such long-term serious serious other severe other such several sure small serious smaller 5-15 higher 5-15 l-2 i young longer common young § 30000-26 serious allergic low temporary less common second serious toll-free toll-free more She-he other child 8- serious unable best most few dis- easy é-l / 4-6 Other same young able serious such long-term older l8 coun- lPV sure serious other severe small serious smaller small close polio small past first 1-26 serious toll-free toll-free more She-he other l/I/ ﬁrst Dur- 3-fold ﬁnal same due large popula- certain smaller secondary large unvaccinated limited comparable same similar 25-year severe lower same preventable routine vaccina- Total paralytic —- final asymptomatic available more acute available §lnvasive confirmed vaccine-associated preventable recent due complete comprehensive least primary invasive lower same increased universal 19-35 old more third modest invasive due other small invasive active such older dramatic pre-Hib-vaccine less due additional invasive most serotype other supplementary available local Editorial adverse effective effective retrospective several future critical other 1978-1 usrs nu small effective prospective rare low second last ten consistent various clinic rural large metropolitan successful public full no-fault adverse vac- individual com- peti- com- vacci- prior pro-1988 post-1988 pre-1988 general specific death-related total future non-reimbursable medical residential custodial-end third-party pre-1 reasonable re- hear- initial com- full intial additional 219- pre-1988 available 3E-RVICE8 pre-1988 general pre-1988 quarterly members-three profes- general more ex-officio ad- compen- vac- 301-443-6593 specific informa- 1-800-338-2382 free no-fault adverse vac- individual com- peti- com- vacci- prior pro-1988 post-1988 general specific post-1 least vaccine first post-1988 vaccine-related death-related future non-reimbursable medical residential custodial ex- third-party reasonable re- hear- initial com- Special specific medical additional individual available post-1988 fol- post-1988 available / quarterly profes- general ex-officio ad- compen- vac- specific inforrna- 1-800-338-2382 free private public paralytic injured legal least vaccine vaccine-related toll-free 1-800-338-2382 further 8A-35 individual special initial special pre-existing vaccine legal complex medical most due unrelated civil last eligible noncompensable many Other unspeciﬁed vaccine-related vaccine-related more such vaccine-related certain civil new restrictive non-compensable new present additional new current few expeditious new routine current statutory retroactive effective Residual Hypotonic-Hyporesponsive new permanent medical adverse longer interested real suspected adverse Other anaphylactic fore- anaphylactic more vaccine more vaccine other non-immunodeficient applicable anaphylactic anaphylactic anaphylactic severe lethal systemic Most few cardiovascular Other signiﬁcant clinical pharynx and-or and-or lower minimal spleen signiﬁcant such applicable such more associated least postictal older least signiﬁcant mental confusional independent intracranial clinical clinical least greater applicable painful other absent external familiar clinical signiﬁcant mental high-pitched unusual inconsolable other neurologic applicable least normal neurologic encephalopathy residual neurologic subsequent secondary genetic chronic encephalopathy metabolic structural genetic metabolic structural genetic unc vaccine-related possible entire medical less additional distinct equal greater equal greater distinct convulsive 24-hour expert neurological particular residual equal greater oral equal greater myoclonic grand complex partial joint objective acute objective continuous more chronic such connective limited systemic systemic mixed connective degenerative infectious other direct immune metabolic neuropathic inﬂammatory syndrome chronic more separate essential possible such other serious other adverse adverse legal adverse s legal available available legal adverse Such local general same possible more adverse serious negative normal relevant abnormal short ear pre-existing physician-diagnosed medical developmental and-or adverse previous more prior additional old Toll-free 1-800-822-7967 confidential Last Patient-Parent Physician Other different .4 adverse permanent diagnostic other office-hospital ] Military clinic-hospital clinic-hospital Other Other Pre-existing physician-diagnosed medical adverse applicable initial 300aa-25 other voluntary 542-650 vaccine-preventable Public due causally- related adverse such many such important public adverse certain serious adverse effective adverse single implement historical cost-effective public ﬂ0542-09 available Vaccine-preventable such congenital uncommon most many major similar rigorous safe effective careful healthy vaccine-preventable beneﬁt-risk dynamic key beneﬁt-risk due adverse due high such universal non-isolated Other such infectious substantial severe progressive effective negligible true adverse relative Reportable Vaccine-toxoid anaphylactic hypotonic-hyporesponsive anaphylactic non-immunodeficient immunodeficient vaccine-associated anaphylactic suspected adverse hypotonic-hyporesponsive such partial complete white unresponsiveness environmental other first mumpe- other grand tonicclonic focal substantial frequent focal neurological intracranial neurological temporary complete various permanent such high-pitched unusual uncontrollable compatible conclusive slow current vaccine-preventable paralytic wild —99.67 1964-6 adverse most reduced vaccine-preventable close temporal greater adverse recent other temporal understood medical such other sudden such inherent possible adverse few higher epidemic former diphtheria- adverse dramatic alternative public high low vaccine-preventable epidemiological causative adverse lower effective routine geographical many vaccine-preventable global possible unlikely such foreseeable new potential adverse close adverse appropriate critical essential current other pharmaceutical undergo possible local systemic clinical adverse adverse possible small few last longer few homogeneous uncommon rare adverse low continuous general such adverse several general constituent such overall new third spontaneous active medical such affordable new adverse national safe other biological available fraudulent most many federal biological many epidemiological such ﬁeld such adverse rapid corrective potential public spontaneous adverse adverse public adverse private Most public private different mandatory implement overall vaccine-preventable ﬁnancial technical close operational other signiﬁcant adverse US-licensed such other obvious adverse narrative adverse demographic medical prior adverse likely general internal public certain adverse other available 24-hour toll-free l-800-822-7967 available such American adverse adverse similar physician outcomeeandadversewentsresultinginm-dayandl-year serious key serious additional direct ongoing monthly available 703-487-4650 serious non-serious adverse serious permanent serious additional alternative extensive similar other such medical third-party such additional such acceptable adverse adverse adverse nationwide vaccine-speciﬁc lot-speciﬁc inform- adverse additional personal such neurological important unreported adverse unusual important new further clinical epidemiological true possible oral possible Such unsubstantiated impossible due small single Unusual adverse adverse vaccine-specific adverse available Under-reporting inadequate important new Toll-free 1-800-822-7967 um Other different __./__./__ adverse diagnostic other Other office-hospital clinic-hospital Other lunknown Pie-existing physician-diagnosed medical adverse mnrmmmmnmmmm-amaummmm epidemiological such adverse live viral wild such several intrinsic spontaneous follow-up necessary Table clinical adverse due true adverse necessary available due adverse adverse rare adverse public under- consistent possible known common adverse random adverse such general other public many adverse clinical same single difficult greatest general adverse aseptic clinical adverse vaccine-associated wild and-or higher adverse other supportive plausible biological reasonable most clinical Most other less necessary epidemiological other two-by-two necessary epidemiological non-controlled clinical useful other necessary adverse possible vaccine adverse large-scale double-blind placebo-controlled clinical adverse effective preventive unethical rare adverse observational epidemiological Such expensive few alternative pharmaco- epidemiological recent large such such universal outpatient potential such epidemiological potential routine such under- large frequent adverse available adverse insidious traditional epidemiological economical rapid new adverse neurological rare adverse demographic medical potential larger greater rare adverse current older adverse older rare potential adverse cost-effective public available adverse necessary public Such critical adverse many inherent spontaneous useful other important signiﬁcant initial permanent 730-733 567-611 3-11 576-5 234-237 sudden 131-132 chronic 215-216 1-24 whooping cross-sectional Swedish 181-188 526-6 264-28 global l- inal lntemational unimmunized 209-217 global 1774-1779 older follow-up 555-661 available 245-256 23-25 Basic 421-422 16-81 Polio-historical induced 413-431 215-259 nationwide 1976-1977 270-278 national 1976-1977 adverse 169-174 3-111 175-179 recommend- oral 153-160 sudden 419-421 sudden possible vaccine-related 751-755 aseptic possible intluehza 1990-61 abstract 5-6 serious epidemiologic 287-297 Molecular 8499-604 wild 7-990 GuiIlain-Barre —- 16-60 253-254 1661-16 infectious available phannacoepidemiologic 13-26 sudden sudden immuniz- 616-623 1641-1645 diphtI'leriHetanUs-pertussls measles-mumps-rubella 881-885 adverse lntemational 26-29 many religious philosophic mandatory personal and-or vaccine-preventable serious effective common concerned specific other anti-vaccine sure common anti-vaccine socioeconomic other survival susceptible actual little signiﬁcant direct modern present periodic real permanent wide other vaccine-preventable similar high least 15-year universal good few available most hard virtual recent other modern several dramatic same annual immediate major former low primary 2-lto 10-fold former anti-vaccine effective true such effective apparent effective Most routine 85-95 hypothetical high entire susceptible unvaccinated several high t —- unvaccinated less most hot adverse considerable hot dangerous other certain serious minor temporary little permanent adverse same several several larger coincidental highest ﬁrst adverse relative hot best worst particular serious adverse legal modern adverse unsafe additional protective product-testing weekly unusual unsafe healthy safe many harmful possible long-term safe much anti- genuine vast adverse minor temporary serious adverse few hard new vaccine-related little low moderate past same fair well-controlled other several likely decreased serious adverse many more serious 71-fold 4-fold due severe full full serious many clear many many more medical effective unconscionable low serious vaccine-related Vaccine-preventable true vaccine-preventable low other same few small few unvaccinated second small small susceptible immune successful successful irresponsible other same different same harmful many foreign new numerous upper viral strep normal unlikely separate available adverse simultaneous normal various American simultaneous such safe effective effective such greater adverse simultaneous routine single individual fewer practical several same possible vulnerable early various same several same fewer traumatic natural foreign speciﬁc non-human passive viral spinal such mucous runny bluish low dead protective viral low injectable immune subclinical asymptomatic particular normal and-or macular papular aseptic bacterial non-speciﬁc salivary intense transplacental immune bright inactive responsible Early larger genetic detectable certain typical same clinical low human synonymous infectious smaller protective Vaccine-Preventable Red American Communicable American related 44:741-6 influenza 1989-91 133-7 6-25 permanent 12:542-50 methodological adverse 136:121-35 adverse 5:169-74 large-linked independent synergistic special supplemental different 274:312-6 vaccine-preventable 43:57-60 2-year-old 43:705-9 vaccine-preventable 43:718-20 national 19-35 public 1985-1993 low 13:385-98 37:153-8 computer-generated pediatric pediatric 1:315-30 1971-81 1393-7 outbreak-Russian 1990-1993 42:840-1 independent former 1990- 44:177-81 Russian due alcoholic urban preschool-aged 1991-1992 43:709-11,717 148:943-9 important public safe efficacious 13:394-407 1993-1994 44:545-50 120:184-9 older 341:864-5 routine 340:592-4 13-42 pharyngeal 164:982-6 high 37:429-32,437 universal human other health-care 377-82,87-8 immune public intradermal 1990-1991 40:569-72 transmission-—United 44:574-5 pneumococ\cal 44:506-7 513-15 322:443-50 performance-based elderly elderly 1778-84 elderly asthmatic Available Laboratory 6:145-51 Mumps-—United 1985-1988 38:101-5 surveillance-—United 119:187-93 13:553-9 medical settings-—United 1985-1989 1989-1990 43:451-63 Surveillance-United pediatric religious 12:288-92 Molecular 1989-1991 11-19 1992-June 44:525-29 44:74-6 adverse 68:650-60 infectious central nervous past 33:107-43 adverse 4243-67 clinical direct clinical 16:276-85 whole-cell 267:2745-49 current 270:1826-31 present 1506-8 pneumococcal 44:506-7 513-5 protective pneumococcal 1453-60 pneumococcal high-risk 315:1318-27 global 1985-1994 44:273-5 historical current 137-43 paralytic oral 13:926-39 paralytic 148:479-85 last indigenous wild virus-associated 14:568-79 new paralytic classic 21:891-903 475-6 congenital 1988-1990 40:93-9 38:289-93 congenital 43:397-401 congenital congenital 14:573-8 pediatric surveillance-—United 1989-1990 1-9 neonatal 396-8 vital 132-42 routine 1375-81 clinical sensitive clinical rapid genetic large possible molecular epidemiological wild-type wild-type critical many possible genetic several measles- available same urine lgM-capture possible urine possible viral sterile suitable isotonic such units-ml ug-ml fetal possible nasal small 3-5 much possible small sterile 2-3 cell- nasal epithelial possible immediate cold possible separate dry available whole dry dry ideal urine adequate 50-100 urine 2-3 dry available available urine entire infectious capable 64:700-705 useful syncytial cytopathogenic visible Isolation-attempt 7-8 subsequent 2-3 possible 895-8 available American units-ml mg-ml ug-ml fetal 5- fetal viral careful single viable lower additional many free-ﬂoating light 30-35 standard 24-48 1-1.5 clinical 3-4 least clinical visible extensive necessary maximal successful immunological such ﬂuorescent original clinical second top top such small dry clinical available pre-paid able 404-639-3512 404-639-3308 404-639-1307 329-8306 329-8245 329-8244 329-8244 329-8246 271-4932 12237-0627 329-8250 329-8251 329-8255 329-8256 329-8256 08625-0369 329-8249 588-7512 08625-0369 329-8249 329-8257 329-8257 329-8258 329-8258 329-8254 576-6418 329-8254 576-7144 329-8254 329-8263 564-4553 27611-7687 329-8265 751-3606 27611-7687 329-8265 576-7130 576-7130 733-7752 329-8273 329-8273 329-8273 329-8266 329-8267 329-8267 466-4643 329-8259 329-8260 265-8366 329-8260 329-8261 329-8261 329-8261 558-2188 487-2755 487-2755 329-8262 329-8264 329-8264 00936-8523 329-8252 329-8282 281-4917 329-8271 329-8271 329-8289 53701-0309 329-8274 329-8269 329-8269 329-8269 329-8269 329-8270 329-8270 329-8284 329-8284 746-5380 329-8284 526-5220 329-8291 329-8276 329-8276 483-1909 87502-6110 329-8277 Indian 329-8028 329-8279 329-8279 329-8280 329-8292 230-5855 329-8292 329-8300 329-8290 329-8305 329-8305 329-8294 687-4800 540-2065 329-8294 329-8294 482-4856 240-7937 -3644 324-0050 329-8297 CDC-NATIONAL other preventive universal Japanese um acellular use-—supplementary acellular fourth fifth supplementary 73-76 31-4 inactivated supplementary viral prevention-—United schedule-—United transmission-—United 669-675 nn-14 new 00-5901 new available early pediatric 00-6221 interim single good 00-6445 00-6337 00-6520 ] 00-6460 00-6526 